63 related articles for article (PubMed ID: 38348846)
1. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
2. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
3. Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases.
Elagawany M; Abdel Ghany LMA; Ibrahim TS; Alharbi AS; Abdel-Aziz MS; El-Labbad EM; Ryad N
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2311157. PubMed ID: 38348846
[TBL] [Abstract][Full Text] [Related]
4. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
5. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
6. 2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
Li ED; Lin Q; Meng YQ; Zhang LY; Song PP; Li N; Xin JC; Yang P; Bao CN; Zhang DQ; Zhang Y; Wang JK; Zhang QR; Liu HM
Eur J Med Chem; 2019 Jun; 172():36-47. PubMed ID: 30939352
[TBL] [Abstract][Full Text] [Related]
7. Novel Pyrimidine-5-Carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFR
Reda N; Mohamed KO; Abdou K; Helwa AA; Elshewy A
Bioorg Chem; 2024 Apr; 145():107185. PubMed ID: 38350273
[TBL] [Abstract][Full Text] [Related]
8. Developing multitarget coumarin based anti-breast cancer agents: synthesis and molecular modeling study.
Takla FN; Bayoumi WA; El-Messery SM; Nasr MNA
Sci Rep; 2023 Aug; 13(1):13370. PubMed ID: 37591917
[TBL] [Abstract][Full Text] [Related]
9. Caffeic acid phenethyl ester suppresses EGFR/FAK/Akt signaling, migration, and tumor growth of prostate cancer cells.
Tseng JC; Wang BJ; Wang YP; Kuo YY; Chen JK; Hour TC; Kuo LK; Hsiao PJ; Yeh CC; Kao CL; Shih LJ; Chuu CP
Phytomedicine; 2023 Jul; 116():154860. PubMed ID: 37201366
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Fallah J; Agrawal S; Gittleman H; Fiero MH; Subramaniam S; John C; Chen W; Ricks TK; Niu G; Fotenos A; Wang M; Chiang K; Pierce WF; Suzman DL; Tang S; Pazdur R; Amiri-Kordestani L; Ibrahim A; Kluetz PG
Clin Cancer Res; 2023 May; 29(9):1651-1657. PubMed ID: 36469000
[TBL] [Abstract][Full Text] [Related]
11. [
Hennrich U; Eder M
Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297404
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of Coumarin Derivatives as Cytotoxic Agents through PI3K/AKT Signaling Pathway Inhibition in HL60 and HepG2 Cancer Cells.
Kishk SM; Eltamany EE; Nafie MS; Khinkar RM; Hareeri RH; Elhady SS; Yassen ASA
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235247
[TBL] [Abstract][Full Text] [Related]
13. Newly Synthesized Pyrazolinone Chalcones as Anticancer Agents via Inhibiting the PI3K/Akt/ERK1/2 Signaling Pathway.
Noser AA; Shehadi IA; Abdelmonsef AH; Salem MM
ACS Omega; 2022 Jul; 7(29):25265-25277. PubMed ID: 35910116
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
